BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Paradigms Foundation - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Paradigms Foundation
X-ORIGINAL-URL:https://paradigms.foundation
X-WR-CALDESC:Events for Paradigms Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20241014T163000
DTEND;TZID=Europe/Paris:20241014T173000
DTSTAMP:20240910T120306Z
CREATED:20240718T123546Z
LAST-MODIFIED:20240910T120306Z
UID:9562-1728923400-1728927000@paradigms.foundation
SUMMARY:Live webinar on the use of generic\, biosimilar and non-biologic complex drugs for multiple sclerosis – Second edition – with German translation!
DESCRIPTION:deutsch \n\n\n\n\n\n\n\n\n\nRegister \n\n\n\nJoin this webinar and familiarise yourself with the robust European regulatory processes and effective oversight for generic\, biosimilar\, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in multiple sclerosis. \n\n\n\nThis webinar will allow you to have informed conversations with your patients about the potential use of these agents and gives a detailed overview of the currently approved generic and biosimilar disease modifying therapies (DMTs). \n\n\n\nRegister now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister today\n\n\n\n\n\n\n\n\nLanguage \n\n\n\nThe session will be held in English. We offer simultaneous translation into German. Submit your questions or give your comments in English or German. \n\n\n\n\n\n\n\nWhy participate? \n\n\n\n\nLearn about the regulatory requirements for generics\, biosimilars and follow-on NBCD’s in Europe.\n\n\n\nUnderstand the clinical considerations for generics\, biosimilars and follow-on NBCD’s in multiple sclerosis.\n\n\n\nGet an overview of the currently approved generic and biosimilar disease modifying therapies for multiple sclerosis.\n\n\n\nHelp your patients make an informed decision.\n\n\n\n\n\n\n\n\nWho should join? \n\n\n\n\nNeurologists with an interest in multiple sclerosis treatments\n\n\n\nNeurologists in training \n\n\n\nNurses involved in MS patient care\n\n\n\nPatient representatives\n\n\n\n\n\n\n\n\nQuestions and comments \n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\n\n\n\n\nTechnology used \n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\n\n\n\n\nDate and time \n\n\n\nThe session will be held in English (with translation in German) on 14th October from 4:30 PM to 5:30 PM CEST. \n\n\n\n\n\n\n\nAbstract of the webinar \n\n\n\nBecause multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease\, the economic burden is substantial\, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs)\, biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access. \n\n\n\nIn Europe\, there are robust regulatory processes and effective oversight for generic\, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents. \n\n\n\n\n\n\n\nOUR SPEAKERS \n\n\n\n\n\n\n\nCelia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid and Professor of Neurology at the University Complutense\, Madrid\, Spain. \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest\, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As a principal investigator\, she has participated in more than 30c MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. \n\n\n\nBesides her clinical and research endeavors\, Professor Oreja-Guevara has held leadership roles in several neurology-focused organizations and academic societies\, such as the Demyelinating Diseases Group and the Neuroimaging Group of the Spanish Neurological Society .Professor Oreja-Guevara is also Co-Chair of the Multiple Sclerosis Panel of the European Academy of Neurology (EAN)\, and serves as an expert for the European Medicines Agency (EMA) and the Spanish Agency of Medicines and Medicinal Products\, highlighting her pivotal role in advancing neurology. \n\n\n\n Conflict if Interest Form – Celia Oreja-Guevara  \n\n\n\n\n\n\n\nThomas Berger\, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna. \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna\, Austria.Scientific interests regard neuroimmunology\, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis\, NMOSD and MOGAD. \n\n\n\nConflict of Interest Form – Thomas Berger \n\n\n\n\n\n\n\nModerator \n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nREGISTRATION \n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nRegister here\n\n\n\n\nThe event is free of charge\, but registration is required. \n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you know a colleague from other regions who would be interested in the topic – kindly share the registration link and invite them to join.  The event is free of charge\, but registration is required. \n\n\n\n\n\n\n\nOUR SPONSOR \n\n\n\nThis webinar is organised with the financial support of Sandoz. Sandoz has not been involved in the elaboration of the presentations. \n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nLive-Webinar über den Einsatz von Generika\, Biosimilars und Arzneimitteln mit komplex zusammengesetzten Wirkstoffen bei Multipler Sklerose – Zweite Auflage – Mit deutscher Übersetzung!\n\n\n\n\n\nenglish \n\n\n\n\n\n\n\nAnmelden \n\n\n\nNehmen Sie an diesem Webinar teil und machen Sie sich vertraut mit den soliden europäischen Regulierungsverfahren und wirksamen Kontrollen bei Generika\, Biosimilars und Folgearzneimitteln mit komplex zusammengesetzten Wirkstoffen (NBCDs) für erkrankungsmodifizierende Therapien der Multiplen Sklerose. \n\n\n\nDieser Webinar wird Sie in die Lage versetzen\, im Hinblick auf den potentiellen Einsatz dieser Arzneimittel gut informiert in den Dialog mit Ihren Patienten zu treten. \n\n\n\nMelden Sie sich jetzt an\, um sich einen Platz zu sichern und am Wissensaustausch und an den Diskussionen teilzunehmen! \n\n\n\n\nHeute noch anmelden\n\n\n\n\n\n\n\n\nSprache \n\n\n\nDie Sitzung wird in englischer Sprache stattfinden. Wir stellen eine Simultanübersetzung ins Deutsche zur Verfügung. Unterbreiten Sie Ihre Fragen oder Ihre Diskussionsbeiträge auf Englisch oder Deutsch. Sie werden dann jeweils in die andere Sprache übersetzt werden. \n\n\n\n\n\n\n\nWarum teilnehmen? \n\n\n\n\nErfahren Sie mehr über die aufsichtsrechtlichen Auflagen für Generika\, Biosimilars und Folge-NBCDs in Europa.\n\n\n\nVerstehen Sie die klinischen Überlegungen bei Generika\, Biosimilars und Folge-NBCDs bei Multipler Sklerose.\n\n\n\nHelfen Sie Ihren Patienten dabei\, ihre Entscheidung mit Sachkenntnis zu treffen.\n\n\n\n\n\n\n\n\nWer sollte teilnehmen? \n\n\n\n\nAuf die Behandlung von MS spezialisierte Neurologen\n\n\n\nIn der Pflege von MS-Patienten tätige Krankenschwestern\n\n\n\nMS-Patienten und die sie pflegenden Personen\n\n\n\n\n\n\n\n\nFragen und Kommentare \n\n\n\nHaben Sie besondere Fragen und würden Sie sie gern diskutiert sehen? Schicken Sie sie jetzt an learning@paradigms.foundation\, damit die Redner sie in Ihren Vorträgen berücksichtigen können.  \n\n\n\nSie werden während des Webinars und der Frage-und-Antwort-Runde auch die Gelegenheit erhalten\, persönlich Fragen zu stellen und sich an den Diskussionen zu beteiligen. \n\n\n\n\n\n\n\nEingesetzte Technik \n\n\n\nDer Webinar wird über Zoom stattfinden. Die Verbindungsdaten werden Sie nach der Anmeldung erhalten. \n\n\n\n\n\n\n\nDatum und Uhrzeit \n\n\n\nDie Sitzung wird am 14. Oktober von 17.30 bis 17:30 MESZ in Englisch (mit Übersetzung ins Deutsche) stattfinden. \n\n\n\n\n\n\n\nDer Webinar kurz zusammengefasst \n\n\n\nDa die Multiple Sklerose (MS) im frühen Erwachsenenalter ausbricht und einen progressiven Krankheitsverlauf kennt\, ist sie mit einer erheblichen finanziellen Belastung verbunden\, wobei ein großer Teil der Gesundheitskosten auf erkrankungsmodifizierende Behandlungen (DMTs) entfällt. Der Einsatz generischer Versionen (oder synthetischer Arzneimittel)\, Biosimilars (für biologische Arzneien) oder Folgeversionen von Arzneimitteln mit komplex zusammengesetzten Wirkstoffen (NBCDs) ermöglicht eine Reduzierung der Gesamtkosten einer MS-Behandlung und eine gesteigerte Erschwinglichkeit für Patienten. \n\n\n\nIn Europa gibt es solide Regulierungsverfahren und wirksame Kontrollen für Generika\, Biosimilars und Folge-NBCDs oder DMTs\, sodass diese Arzneien als gleichwertig gegenüber dem Originalprodukt betrachtet werden können. Ärzte\, die MS-Patienten behandeln\, müssen sich mit den Gegebenheiten vertraut machen\, damit sie ihre Patienten gut informiert im potentiellen Einsatz dieses Arzneimittels beraten können. \n\n\n\n\n\n\n\nUNSERE REDNER \n\n\n\n\n\n\n\nCelia Oreja-Guevara ist Vize-Präsidentin für Neurologie und Leiterin des Centers für Multiple Sklerose an der Universitätsklinik San Carlos\, Madrid\, und Professorin für Neurologie an der Universität Complutense\, Madrid\, Spanien. \n\n\n\nNach Erwerb des Titels eines MD an der Universität Complutense\, Madrid\, erlangte Professor Oreja-Guevara einen Doktortitel in Neuroimmunologie am Max-Planck-Institut für Neurobiologie der Universität München\, München (Deutschland). Im Anschluss daran hat sie eine Facharztausbildung an der neurologischen Fakultät der Universität Bochum (Deutschland) und ein Postdoc-Stipendium in neurologischer Bildgebung an der Universitätsklinik San Raffaele in Mailand (Italien) absolviert. Sie war ebenfalls tätig an der Universität Düsseldorf (Deutschland) sowie an der Klinik Fuenlabrada und der Universitätsklinik La Paz\, beide in Madrid. \n\n\n\nProfessor Oreja-Guevaras Forschungsinteressen konzentrieren sich auf Familienplanung\, Menopause\, Korrelationen bei MS in der neurologischen Bildgebung und die Nutzung der optischen Kohärenztomographie. Neuromyelitis optica (NMO) zählt zu ihren sonstigen bevorzugten Therapiegebieten. Professor Oreja-Guevara ist aktiv an der Beurteilung neuer Arzneimittel für die Behandlung von MS und NMO beteiligt. Als Hauptprüferin hat sie an mehr als 30 klinischen Studien von MS-Arzneimitteln teilgenommen und leitet jetzt ParadigMS\, eine unabhängige internationale Vereinigung von Multiple-Sklerose-Experten ohne Erwerbszweck. \n\n\n\nNeben ihren Test- und Forschungsinitiativen hat Professor Oreja-Guevara leitende Positionen in mehreren der Neurologie gewidmeten Organisationen und akademischen Gesellschaften wie etwa der auf demyelinisierende Krankheiten und der auf neurologische Bildgebung spezialisierten Gruppe der spanischen Gesellschaft für Neurologie innegehabt. Professor Oreja-Guevara ist ebenfalls Vizepräsidentin des Gremiums für Multiple Sklerose der Europäischen Akademie für Neurologie (EAN) und arbeitet als Expertin für die Europäische Arzneimittelagentur (EMA) sowie für die Spanische Agentur für Arzneimittel und Medizinprodukte\, was ihre Schlüsselrolle bei der Förderung der Neurologie unterstreicht. \n\n\n\nInteressenkonflikte-Formular – Celia Oreja-Guevara \n\n\n\n\n\n\n\nThomas Berger\, Professor für Neurologie und Inhaber des Lehrstuhls für Neurologie an der Medizinischen Universität Wien. \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, ist Professor für Neurologie und Inhaber des Lehrstuhls für Neurologie und Leiter des Comprehensive Center for Clinical Neurosciences & Mental Health an der Medizinischen Universität Wien\, Österreich.Sein wissenschaftliches Interesse gilt der Neuroimmunologie\, insbesondere entzündlichen demyelinisierenden Erkrankungen des zentralen Nervensystems mit besonderem Schwerpunkt auf die Erforschung von Körperflüssigkeiten und biologischen Markern bei Multipler Sklerose\, NMOSD (Neuromyelitis-optica-Spektrum-Erkrankungen) und MOGAD (Myelin oligodendrocyte glycoprotein antibody disease – MOG-Antikörpererkrankung). \n\n\n\nInteressenkonflikte-Formular – Thomas Berger \n\n\n\n\n\n\n\nModerator \n\n\n\nStefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nANMELDUNG \n\n\n\nEine Anmeldung ist notwendig und durch Klicken auf die Schaltfläche oben auf dieser Seite oder hier möglich: \n\n\n\n\nAnmeldung\n\n\n\n\nDie Teilnahme an der Veranstaltung ist kostenlos\, aber anmeldepflichtig. \n\n\n\nBeachten Sie bitte: Dies ist ein Live-Webinar\, der sich vorrangig an Neurologen aus Europa\, Nahost und Nordafrika richtet. Sollten Sie einen Kollegen aus anderen Regionen kennen\, die sich für dieses Thema interessieren würde\, geben Sie freundlicherweise den Anmeldelink durch und laden Sie ihn zum Webinar ein.  \n\n\n\n\n\n\n\nUNSER SPONSOR \n\n\n\nDieser Webinar wird mit finanzieller Unterstützung von Sandoz veranstaltet. Sandoz ist an der Ausarbeitung der Vorträge nicht beteiligt.
URL:https://paradigms.foundation/event/live-webinar-on-the-use-of-generic-biosimilar-and-non-biologic-complex-drugs-for-multiple-sclerosis/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/07/LAU-PROD-banner-live-webinar-sessions-1200x627px-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240907T090000
DTEND;TZID=Europe/Paris:20240907T120000
DTSTAMP:20241105T135903Z
CREATED:20240719T151649Z
LAST-MODIFIED:20241105T135903Z
UID:9624-1725699600-1725710400@paradigms.foundation
SUMMARY:Expert Meeting 7th September 2024
DESCRIPTION:On Saturday\, 7th September\, ParadigMS will convene an Expert Meeting in Budapest\, assembling top specialists in multiple sclerosis to review and discuss educational materials on MS treatment and care. \n\n\n\nThe detailed agenda of the meeting: \n\n\n\n\nNEW TOPIC: Consensus quality indicators for the monitoring of multiple sclerosis (Tjalf Ziemssen)\n\n\n\nFINAL PRESENTATION: Beyond EDSS: How to monitor disease progression in multiple sclerosis (Bart Van Wijmeersch)\n\n\n\nNEW TOPIC: Biomarkers (Florian Deisenhammer and Andrew Chan)\n\n\n\nNEW TOPIC: NMO/MOGAD: Diagnosis and Treatment (Celia Oreja-Guevara and Melinda Magyari) \n\n\n\nFINAL PRESENTATION: Generics\, Biosimilars and NBCDs in the Treatment of MS (Thomas Berger (not present) and Celia Oreja-Guevara)\n\n\n\nUpdate on Project: Prognosis Factors in MS (Sofie Aerts)\n\n\n\nDiscussion on future topics and articles status (Celia Oreja-Guevara) \n\n\n\n\nThe final presentations will be shared on our platform shortly. \n\n\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations.
URL:https://paradigms.foundation/event/expert-meeting-7th-september-2024/
ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2024/09/Experts-Budapest-.png
ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240629T080000
DTEND;TZID=Europe/Paris:20240702T200000
DTSTAMP:20240522T142016Z
CREATED:20240522T141930Z
LAST-MODIFIED:20240522T142016Z
UID:9104-1719648000-1719950400@paradigms.foundation
SUMMARY:ParadigMS presence at EAN
DESCRIPTION:The 10th Congress of the European Academy of Neurology (EAN) will take place in Helsinki\, Finland (and online) from 29 June to 2 July 2024. \n\n\n\nThe overarching theme for EAN 2024 is ‘Neuromodulation: advances and opportunities in neurological diseases’\, which will be the focus of several sessions\, with something for every category of participant\, from trainees to specialists\, for both clinicians and scientists.       \n\n\n\nThe congress programme will be bursting with Symposia\, Workshops\, Teaching Sessions\, and much more\, including some exciting named Lectures from top-class line-up of speakers \n\n\n\nParadigMS is excited to join this prestigious event\, where we will have the possibility to showcase our impactful learning initiatives and foster awareness within the neurology community. \n\n\n\nCheck the official website for more information! \n\n\n\n\nEVENT WEBSITE
URL:https://paradigms.foundation/event/paradigms-presence-at-ean/
LOCATION:Messukeskus Expo\, Messuaukio 1\, 00520\, Finland
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/05/LAU-PROD-banner-general-EAN-Congress-2024-1200x600-002_WEBSITE-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240611T153000
DTEND;TZID=Europe/Paris:20240611T163000
DTSTAMP:20240521T144907Z
CREATED:20240404T124944Z
LAST-MODIFIED:20240521T144907Z
UID:8839-1718119800-1718123400@paradigms.foundation
SUMMARY:Live webinar on the use of generic\, biosimilar and non-biologic complex drugs for multiple sclerosis
DESCRIPTION:Register now! \n\n\n\nJoin this valuable and instructive webinar!  \n\n\n\nFamiliarise yourself with the robust European regulatory processes and effective oversight for generic\, biosimilar\, and follow-on non-biologic complex drugs (NBCDs) of disease modifying therapies in multiple sclerosis that allow you to have informed conversations with your patients about the potential use of these agents. \n\n\n\nRegister now to gain insights from experts and ultimately optimize MS treatment strategies and improve patient outcomes! \n\n\n\n\nREGISTER\n\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration.  \n\n\n\nThe session will be held in English (translation in Spanish) on June 11th from 3:30 PM to 4:30 PM CEST. \n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation \n\n\n\n\n\n\n\nWhy participate? \n\n\n\n\n\nLearn about the regulatory requirements for generics\, biosimilars and follow-on NBCD’s in Europe.\n\n\n\nUnderstand the clinical considerations for generics\, biosimilars and follow-on NBCD’s in multiple sclerosis. \n\n\n\n\n\nWho should join? \n\n\n\nNeurologists who deal with multiple sclerosis (MS) treatment and management. Nurses working in the field of multiple sclerosis and patient representatives are also welcome to register.  \n\n\n\n\n\n\n\nAbstract \n\n\n\nBecause multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease\, the economic burden is substantial\, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs)\, biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access. \n\n\n\nIn Europe\, there are robust regulatory processes and effective oversight for generic\, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents. \n\n\n\n\n\n\n\nOUR SPEAKERS \n\n\n\n\n\n\n\nCelia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid and Professor of Neurology at the University Complutense\, Madrid\, Spain. \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest\, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As a principal investigator\, she has participated in more than 30c MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. \n\n\n\nBesides her clinical and research endeavors\, Professor Oreja-Guevara has held leadership roles in several neurology-focused organizations and academic societies\, such as the Demyelinating Diseases Group and the Neuroimaging Group of the Spanish Neurological Society. Professor Oreja-Guevara is also Co-Chair of the Multiple Sclerosis Panel of the European Academy of Neurology (EAN)\, and serves as an expert for the European Medicines Agency (EMA) and the Spanish Agency of Medicines and Medicinal Products\, highlighting her pivotal role in advancing neurology. \n\n\n\nConflict of Interest Form – Celia Oreja-Guevara\n\n\n\n\n\n\n\nThomas Berger\, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna.  \n\n\n\nThomas Berger\, MD\, MSc\, FEAN\, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna\, Austria.Scientific interests regard neuroimmunology\, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis\, NMOSD and MOGAD. \n\n\n\nConflict of Interest Form – Thomas Berger\n\n\n\nModerator: Stefaan De Corte\, General Manager\, ParadigMS \n\n\n\n\n\n\n\nREGISTRATION \n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n\nREGISTER\n\n\n\n\n\n\nPlease note: this is a live webinar primarily for neurologists from Europe\, the Middle-East and North-Africa. Should you not fit this category and should we reach maximum capacity (100)\, we might cancel your registration. \n\n\n\n\n\n\n\nOUR SPONSOR \n\n\n\nThis webinar is organised with the financial support of Sandoz. Sandoz was not involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-on-the-use-of-generics-biosimilars-and-nbcds-for-multiple-sclerosis/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/05/LAU-PROD-banner-live-webinar-sessions-1200x627px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240328T173000
DTEND;TZID=Europe/Paris:20240328T223000
DTSTAMP:20240415T143402Z
CREATED:20240105T104200Z
LAST-MODIFIED:20240415T143402Z
UID:7921-1711647000-1711665000@paradigms.foundation
SUMMARY:ParadigMS 9th Belgian Symposium 2024
DESCRIPTION:ParadigMS Ninth Belgian Symposium promises to be a clinically relevant learning experience\, set against the backdrop of a friendly dinner environment. The event will feature engaging keynotes and clinical case discussions\, providing a unique opportunity for insightful dialogue and professional growth. \n\n\n\nProf. Romain Marignier will share expertise on  \n\n\n\n‘Differential Diagnosis in Multiple Sclerosis\, NMO-SD\, and MOGAD’  \n\n\n\noffering valuable insights that promise to enrich your understanding of these conditions. \n\n\n\nAdditionally\, distinguished clinical biologists\, Mrs. Laurence Lutteri from CHU Liège and Dr. Matthijs Oyaert from UZ Gent\, will present the various diagnostic tests available for MS\, NMO-SD\, and MOGAD.  \n\n\n\nMrs. Lutteri will lead the lecture titled ‘Advances in Clinical Techniques for CNS Inflammatory Diseases‘ in La Hulpe\, and Dr. Oyaert will lead the lecture titled ‘Antibodies in Focus: Advancements in Diagnosing NMO and MOG-related CNS Disorders‘ in Ghent. Their presentations will draw from their extensive hospital experiences\, providing a comprehensive overview of the current diagnostic landscape. \n\n\n\nOur Symposium is helmed by Prof. Bart Van Wijmeersch from UHasselt as the Symposium Chair. Prof. Dominique Dive from CHU Liège and Prof. Guy Laureys from UZ Gent serve as our esteemed Programme Chairs\, facilitating the clinical case discussions. These discussions\, thoughtfully introduced and moderated\, will unfold at each table\, allowing for dynamic interaction and collaborative exploration of challenging cases. \n\n\n\n\n\n\n\n\n\n\nBuy Tickets on Eventbrite\n\nRegister\n\n\n\n\n\n\n\n\n\n\n\nProgrammeSpeakers and abstractsSponsors\n\nMarch 7th\, La HulpeMarch 28th\, Ghent17:45 – 19:00                           Registration and welcome drinks. NetworkingRegistration and welcome drinks. Networking18:15 – 18:45Sponsored break-out AlexionSponsored break-out Alexion19:00 – 19:45Welcome by Mr. Stefaan De Corte\, ParadigMS Manager and by Programme Chair\, Prof. Dominique Dive (CHU Liège) & Main lecture on Differential Diagnosis in MS\, NMO-SD and MOGAD by Prof. Romain Marignier (CHU Lyon)Welcome by Symposium Chair\, Prof. Bart Van Wijmeersch and Programme Chair\, Prof. Guy Laureys (UZGent) & Main lecture on Differential Diagnosis in MS\, NMO-SD and MOGAD by Prof. Romain Marignier (CHU Lyon)19:45 – 20:10First course. Clinical case discussions.First course. Clinical case discussions.20:10 – 20:40Lecture on Advances in Clinical Techniques for CNS Inflammatory Diseases by Dr. Laurence Lutteri (CHU Liège) & Introduction to clinical cases by the Programme Chair and case presentersLecture on Antibodies in Focus: Advancements in Diagnosing NMO and MOG-related CNS Disorders by Dr. Matthijs Oyaert (UZGent) & Introduction to clinical cases by the Programme Chair and case presenters  20:40 – 21:15Main course. Facilitated case presentations and discussions.  Main course. Facilitated case presentations and discussions. 21:15 – 21:45Continued clinical case discussion.  Conclusions by Programme ChairsContinued clinical case discussion.  Conclusions by Programme Chairs21:45 – 22:30Dessert. NetworkingDessert. Networking\n\n\n\n\n\n\n\n\n\nProf. Romain MARIGNIER – MD\, PhD \n\n\n\nPr. Romain Marignier is a neurologist (MD)\, professor in the Neurological Hospital of Lyon\, France. His field of expertise are the neuro-inflammatory disorders of the central nervous system with a specific interest on rare disorders\, namely neuromyelitis optica spectrum disorders (NMOSD) and MOG-Ab associated diseases (MOGAD). Pr Marignier is the coordinator of the French nationwide NMO and MOGAD cohorts and biobanks\, NOMADMUS\, set up in 2010 that includes all the French clinical experts in neuro-inflammatory disorders. Through NOMADMUS\, Pr Marignier provided breakthrough insights in the topic regarding clinical characterization\, management\, and treatment of NMOSD and MOGAD\, supported by major publication in high-profile journals. \n\n\n\nSince 2017\, Pr Marignier is the head of the French referral center for rare inflammatory disorder of the central nervous system (MIRCEM)\, providing expertise on diagnosis and management of NMOSD and MOGAD for both patients and clinicians. \n\n\n\nFinally\, Pr. Marignier achieved a PhD on basic neurosciences in 2011 at Claude Bernard University Lyon 1 on the role of auto-antibodies in NMOSD and related diseases. He actually performs his research at INSERM unit 1028 in Lyon Neuroscience Research Centre (CRNL) on: 1. The pathophysiology of auto antibody- mediated disorders of the central nervous system with in vitro\, ex vivo and animal models; 2. The development of new strategies to optimise detection of auto-antibodies (anti-AQP4\, anti-MOG\, anti-GFAP) for diagnosis and prognosis purpose (immunohistochemistry\, flow cytometry). \n\n\n\nAbstract of talk \n\n\n\nIn the past 20 years\, the concept of antibody mediated demyelinating disorders have emerged. These diseases\, namely Aquaporin-4 (AQP4) positive neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte (MOG)- antibody associated disease (MOGAD)\, share common features with multiple sclerosis\, but are fundamentally different in terms of pathophysiology\, disease course and treatment. In this lecture we will provide a clinical\, biological and imaging description of these two entities\, and propose a focus on the features that helps to differentiate in between these conditions. \n\n\n\nLearning objectives: \n\n\n\n\nto know the diagnostic criteria for NMOSD and MOGAD as compared to MS\n\n\n\n\n\nto identify the situation when to search for AQP4-IgG and/or MOG-IgG  \n\n\n\n\n\nto know the principles of attack and preventive therapies of NMOSD and MOGAD\n\n\n\n\n\n\n\n\n\n\n\n\nDr. Laurence LUTTERI \n\n\n\nDr. Laurence Lutteri has a master in pharmacy and a specialization in laboratory medicine.  \n\n\n\nShe heads the auto-immunity and specialized biochemistry laboratories in the department of clinical chemistry at the University Hospital of Liège. \n\n\n\nShe collaborates in different projects about connective tissue diseases with rheumatologists\, with neurologists for the diagnosis of multiple sclerosis and other inflammatory diseases and also with hematologists for the diagnosis and the follow-up of monoclonal gammopathies. \n\n\n\nImmunofluorescence\, Elisa\, immunodots\,…are the different methods used in her auto-immunity laboratory and electrophoresis\, immunofixation\, turbidimetry\, nephelometry and a lot of different manual techniques in the biochemistry laboratory. \n\n\n\nAbstract of talk \n\n\n\nVarious techniques are used in clinical biology laboratories to diagnose inflammatory diseases of the central nervous system (CNS). Detection of cerebrospinal fluid (CSF)-restricted oligoclonal bands (OCB) has been used for many years to diagnose multiple sclerosis. More recently\, determination of kappa free light chains in CSF/serum has been developed and offers some advantages : fast\, reliable\, rater-independent\, quantitative results – over OCB technique. \n\n\n\nIn the differential diagnosis of demyelinating disorders of the CNS\, the laboratory’s first-line tests are antibodies targeting aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) autoantibodies on transfected cells (fixed Cell Based Assays (CBA)). In the event of clinically inconsistent results\, flow cytometric analysis (live CBA) would show better performance. \n\n\n\n\n\n\n\n\n\n\n\nDr. Matthijs OYAERT \n\n\n\nDr. Matthijs Oyaert graduated as a master in drug development (pharmacy) in 2011 and master in  clinical biology in 2016 at the KU Leuven and started working as a clinical biologist at the clinical laboratory of the Ghent University hospital. In the laboratory of clinical chemistry and hematology\, he is responsible for a broad variety of (automated) routine clinical chemistry and immunochemistry tests and urinary test strip and particle analysis. In addition\, he is involved in the laboratory diagnosis of auto-immune and neuroinflammatory diseases.  \n\n\n\nDuring the first years\, he obtained his PhD in 2021 entitled “New developments in the laboratory diagnosis of urinary tract pathology” at the Ghent University. Besides his activity in the Sciensano expert group of TDM\, chemistry and immunochemistry and member of the European Federation of Laboratory Medicine (EFLM)\, he is an active Member of the current Royal Belgian Society of Laboratory Medicine (RBSLM) board.  \n\n\n\nSince 2021\, he is involved in the EFLM Task and Finish Group on Urinalysis under the supervision of Prof. Dr. Timo Kouri. \n\n\n\nAbstract of talk \n\n\n\nOver the last decade\, knowledge of antibodies linked to inflammatory disorders of the central nervous system\, including forms of neuromyelitis optica (NMO) spectrum disorders\, acute disseminated encephalomyelitis (ADEM)\, optic neuritis and transverse myelitis\, has significantly reshaped the landscape of the diagnosis and clinical care. Notably\, highly specific antibody assays have become an integral part of clinical decision making and include antibodies directed against the aquaporin-4 and anti–myelin oligodendrocyte glycoprotein (MOG). \n\n\n\nVarious assays have been developed to identify and quantify anti-MOG. First generation assays\, including enzyme-linked immunosorbent assays (ELISA) and western blots\, are characterized by a poor sensitivity and specificity. To tackle this disadvantage\, during the past 10 years\, cell-based assays (CBA) in which the recombinant antigen is expressed in its natural confirmation have been developed. Immunofluorescence or flow cytometry is subsequently employed to visualize and quantify antibody binding. Both live and fixed cell CBAs are utilized\, offering enhanced sensitivity and specificity. Moreover\, techniques such as immunoprecipitation provide complementary means for MOG antibody detection\, allowing for confirmation and characterization of MOG antibody subtypes. The selection of an appropriate assay depends on the diagnostic performance\, as well as the laboratory’s technical capabilities. \n\n\n\nDuring this presentation\, the different assays for the detection of anti-NMO and anti-MOG antibodies will be discussed\, including their performance in the different patient populations. Although a lot of progress has already been made in the development\, further efforts need to be undertaken to standardize the different assays. \n\n\n\n\n\nThis valuable learning experience is made possible through the generous support of our sponsors\, whom we sincerely thank. It’s important to note that while our sponsors contribute to the success of the event\, they have no involvement or influence on the learning content itself. We remain committed to providing an unbiased and enriching educational experience for all participants. \n\n\n\nPlatinum \n\n\n\n\n\n\n\nGold \n\n\n\n\n\n\n\n\n\nFAQSponsored breakoutLocations\n\n\nWhen and where is the event taking place?\n\nThe first edition of the ParadigMS Belgian Symposium will take place on Thursday\, 7th of March 2024 at Dolce La Hulpe Hotel in La Hulpe. The second edition of the ParadigMS Belgian Symposium will take place on Thursday\, 28th of March 2024 at Van der Valk Hotel in Ghent.  \n\n\n\n\n\nHow can I register for the event?\n\nSimply click on REGISTER button you can see above this section and then select your preferred event session and sponsored break-out session. \n\n\n\n\n\nIs there a registration fee?\n\nNo\, this learning experience is offered for free to neurologists across Belgium\, Luxembourg and the Netherlands thanks to the support of the sponsors. Registration is mandatory and seats are limited. \n\n\n\n\n\nWill there be any networking opportunities?\n\nThe seated dinner environment will offer plenty of networking opportunities\, in addition to the Welcome drinks and Desert networking. \n\n\n\n\n\nWill there be a sponsor breakout?\n\nYes\, please refer to the programme for more details.  \n\n\n\n\n\nAre there any accommodations nearby?\n\nBoth venues\, located within hotels\, offer convenient accommodation options for participants.\n\n\n\n\n\nIs there parking available at the venue?\n\nBoth venues provide free parking for participants. Please check the Location tab.\n\n\n\n\n\nCan I bring a guest?\n\nYou can register up to 5 persons per session\, if they are also healthcare professionals with a focus on neurology.\n\n\n\n\n\nHow can I get updates or notifications about the event?\n\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\n\nIs there a dress code for the event?\n\nWe recommend wearing smart casual attire.\n\n\n\n\n\nWill there be food and beverages provided?\n\nYes\, we provide a three-course dinner with a variety of drinks. \n\n\n\n\n\nWhat if I need to cancel my registration?\n\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation.\n\n\n\n\n\nHow can I become a sponsor of the event?\n\nIf you wish to become a sponsor of this event\, please send a message to learning@paradigms.foundation. \n\n\n\n\n\nWho can I contact for additional information?\n\nIf you have any questions or need further information about either of the two learning experiences\, please feel free to reach out to us at learning@paradigms.foundation. \n\n\n\n\n\nWhat if organisers need to cancel the event?\n\nThe Symposium is organised by LAUREA Group BV in collaboration with ParadigMS Foundation. The organiser reserves the right to cancel the event at any time due to unforeseen circumstances. In that case\, registrants will be notified by email and no compensation can be claimed. \n\n\n\n\n\nWill this symposium be live streamed?\n\n No\, the two live sessions of the Symposium are not live streamed and available only for onsite participants.\n\n\n\n\n\nWhom can register for one of the sessions?\n\nThe Symposium is open for neurologists\, residents and neuroscience nurses from Belgium\, Luxembourg and the Netherlands. If you do not fall within this category\, please ask for prior approval to the ParadigMS secretariat before registering. If you register without prior approval and are not within the welcomed categories\, the organisers reserve the right to cancel your registration. In case of cancellation\, you will be notified. You can contact us via learning@paradigms.foundation.\n\n\n\n\n\nCan I join both the session in La Hulpe and in Ghent?\n\nNo\, in principle it is not allowed to join both sessions. Please note that both sessions have a very similar programme and are organised in a different language. Should you wish to join both sessions\, please contact us prior to your registration. In case of cancellation\, you will be notified. You can contact us via learning@paradigms.foundation.\n\n\n\n\n\nWill there be a written report from the sessions?\n\nYes\, the ParadigMS Secretariat is planning to have a medical writer on site who will be tasked with producing a written report from both sessions.\n\n\n\n\n\nWill any of the sessions be recorded on video for later viewing?\n\nYes\, the keynote of Prof. Marignier in Ghent will be video and audio recorded and will be made available on ParadigMS.foundation. You will need to create a Member account to have access to the recording (conditions to join as a member apply). \n\n\n\n\n\n\n\n\nKeynote \n\n\n\n‘Precision medicine: targeting complement in the prevention of NMOSD relapses‘ \n\n\n\n\n\n\n\nAbstract of talk \n\n\n\nData presented at the meeting will feature insights from Alexion’s complement portfolio illustrating the critical role of C5 inhibition in treating AQP4 Ab+ NMOSD and significantly reducing the risk of relapses\, including data from the phase III trial with the long-acting C5 complement inhibitor ravulizumab. \n\n\n\n\n\n\n\nSpeakers \n\n\n\n\n\n\n\nProf. Dr. Dominique Dive from CHU Liège  \n\n\n\nMarch 7th\, La Hulpe\, 18:15-18:45 CET \n\n\n\nProf. Dr. Dominique Dive has been working on dysimmune diseases of the central nervous system for more than 30 years; it was the development of evoked potentials that led him to focus on multiple sclerosis\, and particularly paediatric multiple sclerosis.  He is a member of several national and international associations. \n\n\n\n\n\n\n\nProf. Dr. Guy Laureys from UZ Gent  \n\n\n\nMarch 28th\, Ghent\, 18:15-18:45 CET \n\n\n\nProf. Dr. Guy Laureys is the head of the neuroinflammatory care unit at the UZ Ghent Department of neurology. As such he is involved in research\, education and treatment of neuroinflammatory disorders. As a member of the ERN-RITA the neuroinflammatory care unit is a reference centre for rare neuroimmunological disorders such as NMO\, MOGAD\, Susac and autoimmune encephalitis. \n\n\n\n\n\n\n\nPracticalities \n\n\n\nBefore joining the sponsored breakout session\, please stop by the Welcome and Registration desk to collect your badge. You will be guided to the breakout room reserved for each session. \n\n\n\n\n\nParadigMS Ninth Belgian Symposium – 1st edition\, March 7\, 2024 \n\n\n\nLocation: Dolce by Wyndham La Hulpe Brussels  \n\n\n\nAddress: Chau. de Bruxelles 135\, 1310 La Hulpe \n\n\n\n\nParking: Participants can park for free at Dolce La Hulpe Hotel’s two parking spaces (P1 – charging stations available\, and P2)\, and then use the hotel main entrance (the blue bubble in the picture). \n\n\n\n\nRegistration and welcome desk: Participants can collect their badges at the Registration and Welcome desk\, located right after the main entrance.  \n\n\n\n\n\n\n\nParadigMS Ninth Belgian Symposium – 2nd edition\, March 28\, 2024 \n\n\n\nLocation: Van der Valk Hotel Gent \n\n\n\nAddress: Akkerhage 10\, 9000 Gent \n\n\n\n\nParking: Participants can park for free at Van der Valk Hotel Gent’s underground parking spaces (H1\, with parking ticket)\, above-ground parking spaces (H2\, with parking ticket) but also in a second parking lot\, namely the Springpress parking lot\, which is the building opposite the hotel (H3\, no parking ticket). \n\n\n\n\nEntrance: Please use the main entrance and ascend the centrally located circular staircase to reach the first floor\, where the symposium takes place.  \n\n\n\nRegistration and welcome desk: Upon reaching the first floor\, kindly stop to acquire your badge from our registration and welcome desk.
URL:https://paradigms.foundation/event/paradigms-belgian-symposium-2024/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/01/LAU-PROD-banner-general-9th-Symposium-1080x655-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240301T080000
DTEND;TZID=Europe/Paris:20240302T170000
DTSTAMP:20240829T153453Z
CREATED:20240829T153453Z
LAST-MODIFIED:20240829T153453Z
UID:9787-1709280000-1709398800@paradigms.foundation
SUMMARY:INIC 2024
DESCRIPTION:Held from March 1-2\, 2024\, in Riyadh\, Saudi Arabia\, INIC 2024 is the first-ever scientific conference in the region focused on neuroimmunology. Esteemed local and international speakers will deliver cutting-edge presentations aimed at educating both professionals and non-professionals on critical topics such as Multiple Sclerosis (MS) and neuroimmunological diseases. Through these sessions\, the conference is seeking to improve early diagnosis\, enhance interventions\, and empower patients with knowledge and advocacy. \n\n\n\nParadigMS experts are playing a significant role\, presenting on advancements in MS treatments and the integration of AI in personalized medicine. Notable topics include novel therapies targeting microglial cells\, updates on stem cell transplantation for MS\, and the evolving understanding of MS as a continuum of chronic inflammation and disease progression. \n\n\n\nThis groundbreaking conference provides a unique platform for advancing the understanding and management of neuroimmunological diseases\, ultimately aiming to improve patient outcomes across the region. \n\n\n\nThe presentations will be recorded and shared on our platform.
URL:https://paradigms.foundation/event/inic-2024/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2024/08/INIC-24.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231207T190000
DTEND;TZID=Europe/Paris:20231207T200000
DTSTAMP:20240725T120240Z
CREATED:20231103T152902Z
LAST-MODIFIED:20240725T120240Z
UID:7803-1701975600-1701979200@paradigms.foundation
SUMMARY:ParadigMS Pre-MENACTRIMS Symposium 2023
DESCRIPTION:Join us at ParadigMS Pre-MENACTRIMS Symposium!  \n\n\n\nThursday\, 7th of December 2023\, Abu Dhabi\, UAE \n\n\n\nThis unique learning experience focused on advancing excellence in Multiple Sclerosis education and research promises to be a gathering of minds and insights\, with leading experts in the field\, engaging discussions\, and networking opportunities. \n\n\n\nFind out more by exploring the event website and register to secure your spot and be part of this extraordinary live learning experience! \n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations. \n\n\n\n\n\n\n\nMerck Global Medical Education & Academic Organization Relations \n\n\n\nAccess the Merck knowledge forum at http://academe-ms.com/ \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nProgrammeTab SPeakersSponsors\n\n\n\n\n\ntext on speakers \n\n\n\n\n\nThis is content on the sponsors
URL:https://paradigms.foundation/event/paradigms-pre-menactrims-symposium-2023/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2023/11/MSC2023-ParadigMS-Newsletter-2.jpg
ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20230909T090000
DTEND;TZID=Europe/Paris:20230909T150000
DTSTAMP:20240404T125804Z
CREATED:20240404T112701Z
LAST-MODIFIED:20240404T125804Z
UID:8799-1694250000-1694271600@paradigms.foundation
SUMMARY:Expert Meeting 9th of September 2023
DESCRIPTION:On Saturday 9th September\, ParadigMS brings together MS experts to discuss and peer review educational materials on multiple sclerosis treatment and care. A detailed agenda will be shared closer to the meeting but how to uncover subtle/silent progressions is one of the hot topics that will be discussed. \n\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations.
URL:https://paradigms.foundation/event/expert-meeting-9th-of-september-2023/
ATTACH;FMTTYPE=image/webp:https://paradigms.foundation/wp-content/uploads/2024/04/expert-sep-2-3b57c37f-1.webp
ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20230420T173000
DTEND;TZID=UTC:20230420T223000
DTSTAMP:20240522T142508Z
CREATED:20221207T123417Z
LAST-MODIFIED:20240522T142508Z
UID:5122-1682011800-1682029800@paradigms.foundation
SUMMARY:ParadigMS 8th Belgian Symposium 2023
DESCRIPTION:Register now for the eighth ParadigMS Belgian Symposium!\n\n\n\nParadigMS Foundation invites Belgian neurologists\, MS nurses and other interested professionals to mark Thursday 20th April 2023 in their agenda!The workshops\, plenary session\, sponsored break-outs and panel discussions bring you new insights that improve your day-to-day clinical practice. \n\n\n\nWhy participate? \n\n\n\n• As a neurologist or nurse: Get inspired by MS experts and share your own experiences\, meet colleagues and discover the work of other neurologists in the field of MS.• As a resident: Get familiar with this specific field of neurology and build a networking within Belgian MS care.• As an non-health care practitioner: Hear the view of MS experts and connect to the Belgian MS treatment and care community. \n\n\n\nThe top 5 objectives to make your participation a success? \n\n\n\n1. Ask your question or share a comment related to MS treatment and care2. Meet colleagues that work on similar clinical cases3. Get informed on some of the latest news related to MS treatment and care4. Establish new contacts that can support your daily clinical work or research project5. Learn from the international experience from our speakers \n\n\n\n\n\nJoin the live stream\n\n\n\nAs from Monday 17th April\, you find here the links to access the live stream of the ParadigMS Symposium. It allows you to test your connection.  \n\n\n\n\nAccess the live stream of the plenary session via this link.\n\n\n\nAccess the live stream of the Roche sponsored break-out session via this link (Rethinking Treatment Strategies in MS by Dr. Tatjana Reynders).\n\n\n\nAccess the live stream of the Janssen sponsored break-out session via this link (Paradigm shift in first line MS treatment by Dr. Bart Van Wijmeersch).\n\n\n\n\nIMPORTANT: You are directed to a form to leave your details. Once you submit\, you are directed to the page with the live stream. Each time you close the browser window of the live stream\, you can re-enter via the same procedure (leaving your details etc).  \n\n\n\nWe collect your information via this form to be able to accurately evaluate the participation to our Symposium. \n\n\n\nTranslation: You can select your language in the live stream window. If you join onsite\, you can also access the translation via the live stream.  \n\n\n\nQ&A and comments during the plenary session: Submit them via Slido.com with event code: #1434258 or directly in the Slido window available at the right of the live stream window.  \n\n\n\nFees\, translation and accreditation \n\n\n\nThe Symposium is offered for free\, thanks to our sponsors whom were not involved in the elaboration of the scientific programme and presentations.  \n\n\n\nAll plenary sessions are simultaneously translated from English to Dutch and French.  \n\n\n\nRIZIV/INAMI accreditation will be requested for the Workshops (1 hour) and the keynotes and panel discussion (1 hour) – this accreditation applies to Belgian physicians only. \n\n\n\n\n\n\n\nProgrammeWorkshop & Keynote abstractSpeakersSponsorsFAQPracticalSponsored break-outs\n\n\n\nProgrammeParadigMS Belgium Symposium 2021 – Thursday 24th JuneHybrid  \n\n\nTimeProgramme14:00– 17:00Pre-symposium online 1-1 meetings session (online)17:00 – 17:30Pre- symposium on-site 1-1 meetings session ( Van Der Valk) 17:00 – 17:30Welcome coffee Worshop 1 ( at Van Der Valk) 17:30 – 19:00Workshop 1: Risk Manegment in the  Treatment of MS (at Van Der Valk )  Workshop 2: Individualized Prognosis in MS- clinical cases ( online) 18:30 – 19:30Sign-in for the lectures and walking dinner ( at Van Der Vlak ) 19:00 – 19:30Sponsored break-out 1- New approaches to personalised medicine in MS: novel endpoints by BMS ( Van Der Valk and online)Sponsored break out 2- Smouldering part of the disease DMTs- what remains to achieve by Sanofi (online)19:30 – 19:45Welcome and Introduction ( on-site and online) 19:45 – 20:10Keynote and Q&A: Innate Immunity and the Role of Microglia in MS (on-site and online) 20:10 – 20:35Q&A and Panel Discussion on topics of the workshops and the keynote (on-site and online) 21:05 – 21:30Networking with coffee and dessert ( Van Der Valk) 21:05 – 22:15Post-symposium 1-1 meeting session (online)Post-symposium 1-1 meeting session ( Van Der Vlak) \n\n\n\n\n\n\nSpeakerWorkshop AbstractMelinda MagyariReal-life data on switching medicationWhile the increasing number of highly effective immunotherapies for multiple sclerosis has improved disease control\, no disease modifying therapy (DMT) is entirely effective in halting disease activity. Switching DMT should therefore be considered in cases of breakthrough disease or an inadequate response to therapy\, intolerability or specific side effects\, adverse events\, family planning\, compliance issues\, psychosocial reasons\, and economic reasons.The aging MS population also raises the need for de-escalation of DMT\, emphasizing the importance of the risks and benefits of such a switch which should be considered on a case-by-case basis. Real-life data can contribute with evidence on predictors of treatment response\, guide the selection of the most appropriate DMT for individual patients\, and inform treatment decisions when switching DMTs.Vincent Van PeschImmunology and the mechanisms of immune system dysfunctionImmunology is rapidly changing\, increasingly complex and interdisciplinary discipline and has entered the field of neurology for several diseases such as Multiple Sclerosis (MS)\, neuromyelitis optica\, myasthenia gravis or other less common disorders. This workshop will cover basic immunology concepts\, including the different types of immune cells and their function\, as well as the mechanisms of immune system activation and regulation. It will also provide the basis for understanding the role of immune cells and cytokines in the development of MS and the mechanisms of tissue damage\, as well as the mode of action of disease-modifying therapies. Participants will have the opportunity to engage in interactive discussions and case-based learning activities\, allowing for a more in-depth understanding of the functioning of the immune system and its relevance for MS and the treatment of immune-mediated neurological disorders.\n\n\nSpeakerKeynote AbstractNiels HellingsEpstein Barr Virus and Multiple Sclerosis: Old Wine in New Bottles?Epstein Barr Virus (EBV) and its possible involvement in the etiology of multiple sclerosis (MS) has regained a lot of attention lately. But did we really learn something new or do recent reports merely confirm what has been known for many years? Did we get any further than the paradigms which have been textbook knowledge for some time?In my talk\, I will summarize the most important facts on EBV and MS and emphasize the elements that are still unknown and should be subject of future research to get any idea about the pathogenicity of this herpes virus in MS. I will touch upon the limitations of reported studies and conclude by discussing possible therapeutic approaches that target EBV and may be considered once causality can be definitely proven one day. Letizia LeocaniNew technologies in the neurological field (OCT\, evoked potentials\, remote monitoring\, AI): What can I use today? And what is coming?Today\, evoked potentials and OCT are routinely used to detect subclinical involvement of eloquent pathways\, to confirm relapses or to monitor demyelination\, remyelination and axonal loss in trials targeting remyelination and neuroprotection. On the other hand\, extensive research\, also on a large scale\, is being conducted to validate and promote the use of digital technologies for remote monitoring\, with the final aim to ease disease management and to allow to empower self-monitoring by people with MS. All these measures\, to be integrated in the large portfolio already available including biomarkers and neuroimaging\, will require computing power and novel processing techniques\, from statistical approaches to artificial intelligence.\n\n\n\n\n\n\nSpeakerBiographyMelinda Magyari is the director of The Danish Multiple Sclerosis Registry (link: www.dmsr.dk/) and a consultant neurologist at the Danish Multiple Sclerosis Center (COI). Her major research area is in multiple sclerosis and other inflammatory disorders of the central nervous system with a special interest in the changing epidemiology and gender differences. Using nationwide population-based data sources her research addresses questions on comorbidities\, reproductive issues\, risk factors and socioeconomic consequences in multiple sclerosis. She is involved in pharmacoepidemiological studies investigating the effectiveness and long-term safety of disease modifying therapies.Niels Hellings is Director of the Biomedical research Institute (BIOMED) and Professor Immunology at the Faculty of Medicine and Life Sciences of Hasselt University (COI).He graduated as master in bioscience-engineering at the Catholic University of Leuven (1996) and consequently obtained a PhD in immunology at Hasselt University (2000). He was visiting postdoctoral scientist at McGill University (Montréal)\, before returning to Hasselt University to set up his own research group. Currently\, Niels Hellings is director of the biomedical research institute (BIOMED) and professor in immunology at the faculty of Medicine and Life Sciences at Hasselt University. He heads the neuroimmune connections & repair (NIC&R) lab that includes 2 tenure track professors\, 3 post docs\, 15 predocs and 2 technicians and published 110 peer reviewed articles (H factor: 35; >3800 cites). The NIC&R lab focuses on immune mediated central nervous system damage and repair. To study this\, a wide variety of immunological and glial cell assays are applied including functional human in vitro assays and high dimensional flow cytometry. Apart from human in vitro studies\, experimental animal models of neuroinflammation and -repair are up and running. In addition to basic research\, collaborative valorization projects are set up with Flemish and international Biotech and Pharma. Niels Hellings is board member of the Belgian Immunological Society and Flanders Vaccine vzw.Letizia Leocani is Associate professor of Neurology at Vita-Salute San Raffaele University\, Neurologist in the Neurorehabilitation Unit of the Neurological Dep.t and supervisor of the Experimental neurophysiology Unit and of Magnetic IntraCerebral Stimulation (MagICSI) center – Institute of Experimental Neurology\, IRCCS Ospedale San Raffaele (COI). After her medical degree\, she obtained a PhD in Human Physiology and Neurology specialty and she has been Research Fellow at the Human Motor Control Section of the National Institutes of Health in Bethesda-USA. She is Co-Chair of the Clinical Neurophysiology scientific panel of the European Academy of Neurology. Her fields of interest involve translational validation of electrophysiological (advanced EEG analysis\, evoked and cognitive potentials) and structural (optical coherence tomography – OCT) markers of diseases of the central nervous system and of treatment strategies using non invasive brain stimulation to potentiate the effects of drugs and neurorehabilitation.Van Pesch served as neurology resident at the Department of Neurology\, Saint-Luc Hospital and then progressed in positions from Adjunct Clinical Head to Associate Clinical Head and finally to Adjunct Chief of Neurology Department at the Cliniques Universitaires Saint-Luc (COI). He is also responsible for the coordination and supervision of the neurophysiology unit and is consultant for the clinical biology department concerning neuro-immunological analysis. He obtained his medical degree in 1999 from the UCLouvain and then completed his PhD thesis in neuroimmunology in 2003. At the UCLouvain\, Dr Van Pesch is a Professor of Neurology and is responsible for teaching neuroimmunology and cerebrospinal fluid/neurochemistry analysis. He is the Principal investigator of the Neurochemistry Unit at the Institute of Neuroscience currently supervising 2 PhD students. Dr Van Pesch also greatly contributes to scientific publications and has over 169 published papers in a number of renowned journals. He is also co-editor of Frontiers Neurology\, section of Multiple Sclerosis and neuroimmunology and section of Neuroepidemiology and has Co-editor of the Acta Neurologica Belgica between 2014 and 2022.\n\n\nChair  BiographyBart Van Wijmeersch is a neurologist specialized in Multiple Sclerosis. He is medical director of the Rehabilitation and MS Center in Pelt where he leads the multidisciplinary MS-team. Furthermore\, he is an associate professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute\, where he’s involved in pre-clinical as well as the clinical research on MS at the biomedical institute (BIOMED). He has a supporting role in all the immunological research on blood- and CSF samples of persons with MS and in EAE-animal models\, as well as in the rehabilitation research at REVAL. Immunological\, Biomarker\, MRI\, Electrophysiological and Rehabilitation research in MS come together in this way. He has an educational role in the faculty of medicine and physiotherapy.He’s a member of the Belgian Study Group of Multiple Sclerosis\, first President of ParadigMS and a member of advisory boards of different pharmaceutical companies with interest in Multiple Sclerosis.As acknowledgment of his scientific work\, he received an honorary award of the Flemish government in the summer of 2019.\n\n\nModeratorBiographyAs a media professional\, Lies Martens analyzes the errors companies make when they communicate with the press in a crisis. She is an expert\, coach and trainer in crisis communication\, media and presentation skills. Through many years of experience as a journalist\, she is also able to lead a debate and to ask the right questions as an interviewer.\n\n\n\n\n\n\n\n\nPlatinum sponsor \n\n\n\n\n\n\n\n\n\n\n\nPlatinum sponsor \n\n\n\n\n\n\n\n\n\n\n\nGold sponsor \n\n\n\n\n\n\n\n\n\n\n\nGold sponsor \n\n\n\n\n\n\nGold sponsor \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCan I change my registration?\n\n\n\n\nYes\, you can change the selections you made in your registration. Eg.: adding or deleting a specific session.You cannot however\, change an online into an on-site ticket or visa-versa. For this\, you will need to cancel your ticket and register for a new ticket.  \n\n\n\n\n\n\n\n\nI missed a session\, can I watch it somewhere?\n\n\n\n\nAll plenary sessions are recorded and can be watched at this platform.You need to create an account to access all ParadigMS learning materials. \n\n\n\n\n\n\n\n\nWhat happens to my personal data?\n\n\n\n\nParadigMS does not sell or transfers your personal details to any third party except for the following:1) Your first and last name are shared with our sponsors and partners. It allows them to know whom has registered and to invite those health care practitioners not yet registered. We do not share contact details (fe: email address). Should you not wish we share your first and last name with our sponsors and partners\, please let us know at secretariat@paradigms.foundation. 2) ParadigMS uploads your details into its contact database. ParadigMS uses this database to send information on its activities. You can always unsubscribe form that mailinglist.The general data protection policy of the organiser\, can be downloaded here.  \n\n\n\n\n\n\n\n\nCan I cancel my registration?\n\n\n\n\nYes\, you can cancel your registration. Certainly for onsite participants we very much appreciate if you let us know you cannot join – as it allows us to adjust the order for the catering in time.  \n\n\n\n\n\n\n\n\nWhat browser do we use to participate at the event?\n\n\n\n\nThe website is best used via Chrome or Firefox.  \n\n\n\n\n\n\n\n\nTerms and Conditions \n\n\n\n\nThe general terms and conditions of the organiser can be downloaded here. \n\n\n\n\n\n\n\n\nUntil when\, can I register this event?\n\n\n\n\nYou can register onsite until 15th April and online until 20th April. \n\n\n \n\n\n\n\n\n\n\n\nWhen: Thursday 20th April 2023 \n\n\nWhere? \n\n\nOnsite: Brussels Airport (Sheraton Hotel – Brussels Airport\, 1930 Brussel) \n\n\nOnline: Via paradigms.foundation (information to connect will be shared 5 working days beforehand) \n\n\nRegistration fee: free\, but pre-registration is mandatoryInterpretation: Live – From English to Dutch/ FrenchAccreditation: RIZIV/INAMI will be requested for the Workshops (1 hour) and the keynotes and panel discussion (1 hour) \n\n\nHow to get there? \n\n\nBy train: train station Brussels Airport is at walking distance and you avoid the traffic! \n\n\nBy car: carpark 1 at Brussels Airport is closest (and most expensive)\, carpark 2 and 3 are cheaper options and also at walking distance.  \n\n\n\n\n\n\nThe sponsored break-outs are also live streamed\, pre-registration is mandatory. \n\n\nFor both break-out sessions are only open for prescribing physicians. \n\n\nSponsorTopicParadigm shift in first line MS treatment by Dr. Bart Van Wijmeersch*Please note this beak-out session is only open for prescribing physiciansRethinking Treatment Strategies in MS by Dr. Tatjana Reynders*Please note this beak-out session is only open for prescribing physicians\n\n\nSpeakerBiographyBart Van Wijmeersch is a neurologist specialized in Multiple Sclerosis. He is medical director of the Rehabilitation and MS Center in Pelt where he leads the multidisciplinary MS-team. Furthermore\, he is an associate professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute\, where he’s involved in pre-clinical as well as the clinical research on MS at the biomedical institute (BIOMED). He has a supporting role in all the immunological research on blood- and CSF samples of persons with MS and in EAE-animal models\, as well as in the rehabilitation research at REVAL. Immunological\, Biomarker\, MRI\, Electrophysiological and Rehabilitation research in MS come together in this way. He has an educational role in the faculty of medicine and physiotherapy.He’s a member of the Belgian Study Group of Multiple Sclerosis\, first President of ParadigMS and a member of advisory boards of different pharmaceutical companies with interest in Multiple Sclerosis.As acknowledgment of his scientific work\, he received an honorary award of the Flemish government in the summer of 2019.Tatjana Reynders studied medicine at UHasselt (Bachelor) and UGent (Master)\, after which she trained as a neurologist at the Free University of Brussels (VUB). Since 2018\, she has been working full time at the UZA as a neurologist with expertise in multiple sclerosis (MS) and neuroinflammatory diseases. In addition\, within neurophysiology\, she has developed strongly in evoked potentials and intraoperative neuromonitoring. In 2020\, she received a PhD in medical sciences from the VUB entitled: “The role of the gut microbiome and the autonomic nervous system in multiple sclerosis.” Her scientific interests lie in clinical and translational aspects of mechanisms of genesis and treatment of neuroinflammatory diseases\, including multiple sclerosis (MS)\, neurosarcoidosis and cerebral vasculitis.
URL:https://paradigms.foundation/event/8th-paradigms-belgian-symposium-thursday-20th-april-2023-brussels-airport/
LOCATION:Sheraton Hotel – Brussels Airport\, Brussels Airport\, Brussel\, 1930\, Belgium
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2022/12/LAU-PROD-banner-general-8th-Symposium-e1673870240166.jpg
ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20230318T090000
DTEND;TZID=Europe/Paris:20230318T113000
DTSTAMP:20240923T085835Z
CREATED:20240404T114654Z
LAST-MODIFIED:20240923T085835Z
UID:8809-1679130000-1679139000@paradigms.foundation
SUMMARY:Expert Meeting 18th of March 2023
DESCRIPTION:ParadigMS board members meet virtually in March. At the Expert Meetings\, experts peer review each others educational slide decks with the objective to publish educational materials for clinical neurologists and nurses on behalf of ParadigMS. \n\n\n\nHere is the agenda of the meeting: \n\n\n\nSlide decks \n\n\n\n\nFINAL REVIEW: Paediatric MS – Lead: Melinda Magyari\n\n\n\nNEW: Cerebrospinal fluid (CSF) in the diagnosis of MS – Lead: Florian Deisenhammer\n\n\n\nNEW: Cognition in MS – Lead: Carlo Pozzilli and Bart Van Wijmeersch\n\n\n\n\nE-learning \n\n\n\n\nMicroglia and MS: Status\n\n\n\nNEW: max 1-hour asynchronous e-learning on how to uncover subtle\, silent progression in MS: Lead expert (max 2) to be assigned.
URL:https://paradigms.foundation/event/expert-meeting-18th-of-march-2023/
ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2024/04/WP-posts-ParadigMS-18.png
ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221110
DTEND;VALUE=DATE:20221111
DTSTAMP:20230314T114940Z
CREATED:20221208T081604Z
LAST-MODIFIED:20230314T114940Z
UID:5152-1668038400-1668124799@paradigms.foundation
SUMMARY:ParadigMS-Pre-MENACTRIMS Symposium 2022
DESCRIPTION:As a warm-up for the Seventh MENACTRIMS Congress\, ParadigMS Foundation is organising an enriching Pre-MENACTRIMS Symposium on Thursday November 10\, 2022.\nThe Seventh Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) Congress will take place November 11 & 12\, 2022 at the Al Hambra\, Intercontinental City Stars\, Cairo\, Egypt\n\nPre-MENACTRIMS Symposium\n\nDate & Time:Thursday\, November 10\, 2021 at 18:30 (EET)\nLocation: Al Hambra\, Intercontinental City Stars\, Cairo\, Egypt\nAgenda:\n\n\n\n\n\n\n18:30 – 19:00\nRegistration and Welcome Coffee\n\n\n19:00 – 19:05\nWelcome by the chairs: Bassem Yamout and Celia Oreja-Guevara\n\n\n19:05 – 19:20\nLaura Airas\, Microglia\, The Basics\n\n\n19:20 – 19:35\nCelia Oreja-Guevara\, Microglia\, How to Target\n\n\n19:35 – 19:50\nCarlo Pozzilli\, Cognition in MS\, A Marker of Silent Progression?\n\n\n19:50 – 20:00\nLive Q&A and Panel Discussion\n\n\n\n\n\n\n\nWatch the on-demand webinars\n\nMore information about the MENACTRIMS Congress\n\nThe congress aim is to provide a forum of excellence in MS education and research. Building on the collective efforts of the scientific committee\, the meeting will deliver state-of-the-art presentations on MS by renowned international and regional keynote speakers. The content of the meeting includes up to date information on the latest treatments\, clinical research\, therapeutic strategies\, pathology\, imaging\, epidemiology\, diagnosis\, biomarkers\, neuromyelitis optica\, and much more.\n\nAdditional information can be found here.\n\n\n\nWith the support of :\nMerck\, Global Medical Education & Academic Organization Relations\nAccess the Merck knowledge forum at academe-ms.com
URL:https://paradigms.foundation/event/paradigms-pre-menactrims-symposium-2022/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2022/10/AdobeStock_289858374-bnw-1-scaled.jpeg
ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20221020T183000
DTEND;TZID=Europe/Paris:20221020T220000
DTSTAMP:20240404T125925Z
CREATED:20240404T122239Z
LAST-MODIFIED:20240404T125925Z
UID:8828-1666290600-1666303200@paradigms.foundation
SUMMARY:ParadigMS Master Class – 20th October 2022
DESCRIPTION:The Master Class aims to bring together health care practitioners participating both on site as well as online\, by offering a learning experience that can positively impact your clinical practice. Question and answer sessions and polls will be used to encourage participants to get involved and engage with the speakers and other participants. \n\n\n\n\n\n\n\nDATE & LOCATION \n\n\n\nThursday 20th October 2022Hybrid event – on site (Health Avenue\, Ikaroslaan 57\, 1930 Zaventem) and online. \n\n\n\nSTORY-LINE \n\n\n\nMS prognostication in practice: today and future perspectives \n\n\n\nMS prognostication provides the neurologist with a comprehensive overview of each patient’s current and potential future disease status. It can be used to identify ‘red flags’ in the patient’s profile indicating the need for heightened vigilance and/or a more aggressive treatment approach. \n\n\n\nIn this one-hour masterclass\, MS neurologists present three related subjects. First\, a prognostication tool is presented that can be used by neurologists in clinical practice. Next\, cases are presented where high efficacy pharmacological treatment is used depending on demographic factors\, clinical manifestations\, MRI observations and biomarkers. We conclude the session with a view on the potential of virtual care and digital biomarkers to complement the available patient data for a neurologist. \n\n\n\nPROGRAMME \n\n\n\n\n\n\n\nSPEAKERS \n\n\n\n\n\n\n\nWHO’S INVITED \n\n\n\nNeurologists • Neurologists in training • Nurses • Researchers • Rehabilitation professionals • Medical professionals
URL:https://paradigms.foundation/event/paradigms-master-class-20th-october-2022/
ATTACH;FMTTYPE=image/webp:https://paradigms.foundation/wp-content/uploads/2024/04/Master-Class-_-black-and-white-600-×-400-px-723dfce7.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20220917T090000
DTEND;TZID=Europe/Paris:20220917T140000
DTSTAMP:20240404T130011Z
CREATED:20240404T115249Z
LAST-MODIFIED:20240404T130011Z
UID:8813-1663405200-1663423200@paradigms.foundation
SUMMARY:Expert Meeting 17th of September 2022
DESCRIPTION:This report provides a summary of scientific proceedings from the ParadigMS Expert Meeting. \n\n\n\nThe following ‘hot topics’ were on the agenda: \n\n\n\n\nPaediatric MS – Lead: Melinda Magyari\n\n\n\nCerebrospinal fluid (CSF) in the diagnosis of MS – Lead: Florian Deisenhammer\n\n\n\nCognition in MS – Lead: Carlo Pozzilli and Bart Van Wijmeersch\n\n\n\nTele-medicine and the use of digital tools in MS – Lead: Mona AlKhawajah\n\n\n\nOCT and microglia – Lead: Celia Oreja-Guevara
URL:https://paradigms.foundation/event/expert-meeting-17th-of-september-2022/
ATTACH;FMTTYPE=image/webp:https://paradigms.foundation/wp-content/uploads/2024/04/Capture-3-d936e18b.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20220908T180000
DTEND;TZID=Europe/Paris:20220908T213000
DTSTAMP:20240522T142638Z
CREATED:20240404T120421Z
LAST-MODIFIED:20240522T142638Z
UID:8818-1662660000-1662672600@paradigms.foundation
SUMMARY:ParadigMS 8th Egypt Symposium on 8th and 9th of September 2022
DESCRIPTION:Save the Date! ParadigMS organises\, in collaboration with the Egyptian MS Society\, a two-day symposium that takes place from Thursday 8th September 2022 through Friday 9th September 2022 in Cairo\, Egypt. \n\n\n\nThe symposium brings ParadigMS’ peer reviewed presentations and workshops to Egypt and is an opportunity for both the presenters and participants to discuss on MRI\, latest available treatments\, immunosenescence\, prognosis in MS\, high efficacy treatments and family planning in a North-African context. The Symposium is sponsored by Novartis Egypt. \n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations.
URL:https://paradigms.foundation/event/8th-paradigms-egypt-symposium-on-8th-and-9th-of-september-2022/
ATTACH;FMTTYPE=image/webp:https://paradigms.foundation/wp-content/uploads/2024/04/Wordpress-presentation-7-a9d935c4.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20220630T173000
DTEND;TZID=Europe/Paris:20220630T223000
DTSTAMP:20240522T142555Z
CREATED:20240404T123326Z
LAST-MODIFIED:20240522T142555Z
UID:8835-1656610200-1656628200@paradigms.foundation
SUMMARY:ParadigMS 7th Belgian Symposium – 30th June 2022
DESCRIPTION:We have chosen to offer a hybrid event\, featuring national and international speakers. (RIZIV/INAMI-accredited). \n\n\n\nAs in previous years\, the workshops and plenary session will provide you with knowledge that you can put to immediate use in your day-to-day practice. \n\n\n\nDATE & LOCATIONThursday 30th June 2022\, from 5.30 pmHybrid symposium – you can follow the symposium digitally or be there in person at the Van Der Valk Brussels Airport hotel in Machelen. \n\n\n\nTOPICS \n\n\n\n\nOnsite workshops on MRI & OCT and MS & Cognition\n\n\n\nOnsite and online keynotes and a panel discussion on precision medicine in MS and the concept of an MS care unit.\n\n\n\n\nWHO’S INVITED \n\n\n\nNeurologists • Neurologists in training • Nurses • Researchers • Rehabilitation professionals • Medical professionals  \n\n\n\nTOPICS \n\n\n\n\nOnsite workshops
URL:https://paradigms.foundation/event/7th-paradigms-belgian-symposium-30th-june-2022/
ATTACH;FMTTYPE=image/webp:https://paradigms.foundation/wp-content/uploads/2024/04/iStock-1224215350-1200x800-2-e1642518653906-d66a3420.webp
END:VEVENT
END:VCALENDAR